Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. · 2019

Read Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. by Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6436208.txt.

Description

Dochez and co-authors update the evidence on blood markers and scoring algorithms used to tell ovarian cancer from benign pelvic masses. Ovarian cancer is usually found late, with more than 70 percent of cases diagnosed at an advanced stage. The standard marker CA125 misses many early cancers and rises for harmless reasons such as menstruation and endometriosis.

HE4, a second marker, reached 94 percent specificity and stays steady with endometriosis cysts, though smoking and contraception shift its levels. Pairing CA125 with HE4 performed best, with an area under the curve up to 0.96. The RMI score reached 92 percent specificity but a weaker 0.86 overall, and ROMA trailed HE4 on specificity.

Catalog record

CREATORDochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6436208

Browse the full library · About the Tower of Babel